Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756–70.
Article
PubMed
Google Scholar
Baumgart DC, Sandborn WJ. Crohn's disease. Lancet. 2012;380:1590–605.
Article
PubMed
Google Scholar
Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12:205–17.
Article
PubMed
Google Scholar
Cleynen I, Boucher G, Jostins L, Schumm LP, Zeissig S, Ahmad T, Andersen V, Andrews JM, Annese V, Brand S, et al. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet. 2016;387:156–67.
Article
PubMed
PubMed Central
Google Scholar
Geboes K, Colombel J-F, Greenstein A, Jewell DP, Sandborn WJ, Vatn MH, Warren B, Riddell RH, Pathology Task Force of the International Organization of Inflammatory Bowel Diseases. Indeterminate colitis: a review of the concept--what's in a name? Inflamm Bowel Dis. 2008;14:850–57.
Article
PubMed
Google Scholar
Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, Simoens S, Rutgeerts P, Gils A, Vermeire S. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148:1320–29.
Article
CAS
PubMed
Google Scholar
Steenholdt C, Brynskov J, Thomsen O, Munck LK, Fallingborg J, Christensen LA, Pedersen G, Kjeldsen J, Jacobsen BA, Oxholm AS, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: A randomised, controlled trial. Gut. 2014;63:919–27.
Article
PubMed
Google Scholar
Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:644–59.
Article
CAS
PubMed
Google Scholar
Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009;104:760–67.
Article
CAS
PubMed
Google Scholar
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–49.
Article
CAS
PubMed
Google Scholar
Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med. 2013;369:754–62.
Article
CAS
PubMed
Google Scholar
Leal RF, Planell N, Kajekar R, Lozano JJ, Ordás I, Dotti I, Esteller M, Masamunt MC, Parmar H, Ricart E, et al. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-tnfα therapy. Gut. 2015;64:233–42.
Article
CAS
PubMed
Google Scholar
Arijs I, Li K, Toedter G, Quintens R, Van Lommel L, Van Steen K, Leemans P, De Hertogh G, Lemaire K, Ferrante M, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut. 2009;58:1612–19.
Article
CAS
PubMed
Google Scholar
Arijs I, Quintens R, Van Lommel L, Van Steen K, De Hertogh G, Lemaire K, Schraenen A, Perrier C, Van Assche G, Vermeire S, et al. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease. Inflamm Bowel Dis. 2010;16:2090–98.
Article
PubMed
Google Scholar
Bjerrum JT, Nielsen OH, Hao F, Tang H, Nicholson JK, Wang Y, Olsen J. Metabonomics in ulcerative colitis: Diagnostics, biomarker identification, and insight into the pathophysiology. J Proteome Res. 2010;9:954–62.
Article
CAS
PubMed
Google Scholar
Bjerrum JT. Metabonomics: analytical techniques and associated chemometrics at a glance. Methods Mol Biol. 2015;1277:1–14.
Article
CAS
PubMed
Google Scholar
Dawiskiba T, Deja S, Mulak A, Ząbek A, Jawień E, Pawełka D, Banasik M, Mastalerz-Migas A, Balcerzak W, Kaliszewski K, et al. Serum and urine metabolomic fingerprinting in diagnostics of inflammatory bowel diseases. World J Gastroenterol. 2014;20:163–74.
Article
CAS
PubMed
PubMed Central
Google Scholar
Fathi F, Oskouie AA, Tafazzoli M, Naderi N, Sohrabzedeh K, Fathi S, Norouzinia M, Nejad Rostami M. Metabonomics based NMR in Crohn's disease applying PLS-DA. Gastroenterol Hepatol Bed Bench. 2013;6:S82–86.
PubMed
PubMed Central
Google Scholar
Zhang Y, Lin L, Xu Y, Lin Y, Jin Y, Zheng C. (1)H nmr-based spectroscopy detects metabolic alterations in serum of patients with early-stage ulcerative colitis. Biochem Biophys Res Commun. 2013;433:547–51.
Article
CAS
PubMed
Google Scholar
Williams HRT, Willsmore JD, Cox IJ, Walker DG, Cobbold JFL, Taylor-Robinson SD, Orchard TR. Serum metabolic profiling in inflammatory bowel disease. Dig Dis Sci. 2012;57:2157–65.
Article
CAS
PubMed
Google Scholar
Schicho R, Shaykhutdinov R, Ngo J, Nazyrova A, Schneider C, Panaccione R, Kaplan GG, Vogel HJ, Storr M. Quantitative metabolomic profiling of serum, plasma, and urine by (1)H NMR spectroscopy discriminates between patients with inflammatory bowel disease and healthy individuals. J Proteome Res. 2012;11:3344–57.
Article
CAS
PubMed
PubMed Central
Google Scholar
Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, Ochsenkühn T, Orchard T, Rogler G, Louis E, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis. 2010;4:7–27.
Article
PubMed
Google Scholar
Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel J-F, Vermeire S, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: Definitions and diagnosis. J Crohns Colitis. 2012;6:965–90.
Article
PubMed
Google Scholar
Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–29.
Article
CAS
PubMed
Google Scholar
Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1:514.
Article
CAS
PubMed
Google Scholar
Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD study group. J Clin Gastroenterol. 1995;20:27–32.
Article
CAS
PubMed
Google Scholar
Afif W, Loftus EV, Faubion WA, Kane SV, Bruining DH, Hanson KA, Sandborn WJ. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:1133–39.
Article
CAS
PubMed
Google Scholar
Steenholdt C, Bendtzen K, Brynskov J, Thomsen O, Ainsworth MA. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol. 2011;46:310–18.
Article
CAS
PubMed
Google Scholar
Dong F, Zhang L, Hao F, Tang H, Wang Y. Systemic responses of mice to dextran sulfate sodium-induced acute ulcerative colitis using (1)H NMR spectroscopy. J Proteome Res. 2013;12:2958–66.
Article
CAS
PubMed
Google Scholar
Zhang X, Wang Y, Hao F, Zhou X, Han X, Tang H, Ji L. Human serum metabonomic analysis reveals progression axes for glucose intolerance and insulin resistance statuses. J Proteome Res. 2009;8:5188–95.
Article
CAS
PubMed
Google Scholar
Nicholson JK, Foxall PJ, Spraul M, Farrant RD, Lindon JC. 750 mhz 1H and 1H-13C NMR spectroscopy of human blood plasma. Anal Chem. 1995;67:793–811.
Article
CAS
PubMed
Google Scholar
Bjerrum JT, Wang Y, Hao F, Coskun M, Ludwig C, Günther U, Nielsen OH. Metabonomics of human fecal extracts characterize ulcerative colitis, Crohn's disease and healthy individuals. Metabolomics. 2015;11:122–33.
Article
CAS
PubMed
Google Scholar
Bylesjö M, Rantalainen M, Cloarec O, Nicholson JK, Holmes E, Trygg J. OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification. J Chemom. 2006;20:341–51.
Article
Google Scholar
Trygg J, Wold S. Orthogonal projections to latent structures (O-PLS). J Chemom. 2002;16:119–28.
Article
CAS
Google Scholar
Cloarec O, Dumas ME, Trygg J, Craig A, Barton RH, Lindon JC, Nicholson JK, Holmes E. Evaluation of the orthogonal projection on latent structure model limitations caused by chemical shift variability and improved visualization of biomarker changes in 1H NMR spectroscopic metabonomic studies. Anal Chem. 2005;77:517–26.
Article
CAS
PubMed
Google Scholar
Eriksson L, Trygg J, Wold S. CV-ANOVA for significance testing of PLS and OPLS models. J Chemom. 2008;22:594–600.
Article
CAS
Google Scholar
Popa C, Netea MG, van Riel PLCM, van der Meer JWM, Stalenhoef AFH. The role of tnf-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res. 2007;48:751–62.
Article
CAS
PubMed
Google Scholar
Singh S, Kullo IJ, Pardi DS, Loftus EV. Epidemiology, risk factors and management of cardiovascular diseases in IBD. Nat Rev Gastroenterol Hepatol. 2014;12:26–35.
Article
PubMed
Google Scholar
Koutroubakis IE, Oustamanolakis P, Malliaraki N, Karmiris K, Chalkiadakis I, Ganotakis E, Karkavitsas N, Kouroumalis EA. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2009;21:283–88.
Article
CAS
PubMed
Google Scholar
Parmentier-Decrucq E, Duhamel A, Ernst O, Fermont C, Louvet A, Vernier-Massouille G, Cortot A, Colombel J-F, Desreumaux P, Peyrin-Biroulet L. Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease. Inflamm Bowel Dis. 2009;15:1476–84.
Article
PubMed
Google Scholar
Pedersen J, LaCasse EC, Seidelin JB, Coskun M, Nielsen OH. Inhibitors of apoptosis (iaps) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation. Trends Mol Med. 2014;20:652–65.
Article
CAS
PubMed
Google Scholar
Holmes-McNary MQ, Baldwin AS, Zeisel SH. Opposing regulation of choline deficiency-induced apoptosis by p53 and nuclear factor kappab. J Biol Chem. 2001;276:41197–1204.
Article
CAS
PubMed
Google Scholar
Syme C, Czajkowski S, Shin J, Abrahamowicz M, Leonard G, Perron M, Richer L, Veillette S, Gaudet D, Strug L, et al. Glycerophosphocholine metabolites and cardiovascular disease risk factors in adolescents: a cohort study. Circulation. 2016;134:1629–36.
Article
CAS
PubMed
Google Scholar
Liu J, Litt L, Segal MR, Kelly MJS, Pelton JG, Kim M. Metabolomics of oxidative stress in recent studies of endogenous and exogenously administered intermediate metabolites. Int J Mol Sci. 2011;12:6469–501.
Article
CAS
PubMed
PubMed Central
Google Scholar
Voet D, Voet JG, Pratt CW. Principles of biochemistry. Hoboken, NJ, Chichester: John Wiley; 2012.
Google Scholar
Morgan MY, Milsom JP, Sherlock S. Plasma ratio of valine, leucine and isoleucine to phenylalanine and tyrosine in liver disease. Gut. 1978;19:1068–73.
Article
CAS
PubMed
PubMed Central
Google Scholar
Freund HR, Ryan JA, Fischer JE. Amino acid derangements in patients with sepsis: Treatment with branched chain amino acid rich infusions. Ann Surg. 1978;188:423–30.
Article
CAS
PubMed
PubMed Central
Google Scholar
Scholl-Bürgi S, Schroecksnadel S, Jenny M, Karall D, Fuchs D. Chronic immune stimulation may cause moderate impairment of phenylalanine 4-hydroxylase. Pteridines. 2011;22:120–25.
Article
Google Scholar
Lamarre SG, Morrow G, Macmillan L, Brosnan ME, Brosnan JT. Formate: an essential metabolite, a biomarker, or more? Clin Chem Lab Med. 2013;51:571–78.
Article
CAS
PubMed
Google Scholar
Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426–31.
Article
CAS
PubMed
PubMed Central
Google Scholar
Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12:537–45.
Article
CAS
PubMed
Google Scholar
Coskun M, Vermeire S, Nielsen OH. Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci. 2017;38:127–42.
Article
CAS
PubMed
Google Scholar